Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Jon A. Kyte"'
Autor:
Hege O. Ohnstad, Elin Borgen, Ragnhild S. Falk, Tonje G. Lien, Marit Aaserud, My Anh T. Sveli, Jon A. Kyte, Vessela N. Kristensen, Gry A. Geitvik, Ellen Schlichting, Erik A. Wist, Therese Sørlie, Hege G. Russnes, Bjørn Naume
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-12 (2017)
Abstract Background The aim of this study was to investigate the prognostic value of the PAM50 intrinsic subtypes and risk of recurrence (ROR) score in patients with early breast cancer and long-term follow-up. A special focus was placed on hormone r
Externí odkaz:
https://doaj.org/article/a45dab2fcc384c7eab60ce8a11289adf
Autor:
Sudhir Kumar Chauhan, Claire Dunn, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Gjertrud Skorstad, Adam Sike, Bjørnar Gilje, Sunil Xavier Raj, Kanutte Huse, Bjørn Naume, Jon Amund Kyte
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-17 (2024)
Abstract Immunotherapies blocking the PD-1/PD-L1 checkpoint show some efficacy in metastatic breast cancer (mBC) but are often hindered by immunosuppressive mechanisms. Understanding these mechanisms is crucial for personalized treatments, with perip
Externí odkaz:
https://doaj.org/article/21138a5be7fa4ef6868ac4e8d5f2a5bf
Autor:
Ragnhild Sørum Falk, Bjornar Gilje, Andrea Gombos, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Beate Boge, Randi R. Mathiesen, Lars Julsrud, Øystein Garred, Hege G. Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire Dunn, Bjørn Naume, Jon Amund Kyte
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Immune checkpoint inhibitors have shown minimal clinical activity in hormone receptor-positive metastatic breast cancer (HR+mBC). Doxorubicin and low-dose cyclophosphamide are reported to induce immune responses and counter regulatory T ce
Externí odkaz:
https://doaj.org/article/e9ba64ad31414caeaea3d72626619d91
Autor:
Yixin Jin, Kristina Berg Lorvik, Yang Jin, Carole Beck, Adam Sike, Irene Persiconi, Emilie Kvaløy, Fahri Saatcioglu, Claire Dunn, Jon Amund Kyte
Publikováno v:
Molecular Therapy: Oncolytics, Vol 26, Iss , Pp 189-206 (2022)
Chimeric antigen receptors (CARs) that retarget T cells against CD19 show clinical efficacy against B cell malignancies. Here, we describe the development of a CAR against the six-transmembrane epithelial antigen of prostate-1 (STEAP1), which is expr
Externí odkaz:
https://doaj.org/article/78ece43bd6684e589e295a37b73f23e1
Autor:
Åslaug Helland, Hege G. Russnes, Gro Live Fagereng, Khalid Al-Shibli, Yvonne Andersson, Thomas Berg, Line Bjørge, Egil Blix, Bodil Bjerkehagen, Sigmund Brabrand, Marte Grønlie Cameron, Astrid Dalhaug, Dalia Dietzel, Tom Dønnem, Espen Enerly, Åsmund Flobak, Sverre Fluge, Bjørnar Gilje, Bjørn Tore Gjertsen, Bjørn Henning Grønberg, Kari Grønås, Tormod Guren, Hanne Hamre, Åse Haug, Daniel Heinrich, Geir Olav Hjortland, Eivind Hovig, Randi Hovland, Ann-Charlotte Iversen, Emiel Janssen, Jon Amund Kyte, Hedda von der Lippe Gythfeldt, Ragnhild Lothe, Jo-Åsmund Lund, Leonardo Meza-Zepeda, Monica Cheng Munthe-Kaas, Olav Toai Duc Nguyen, Pitt Niehusmann, Hilde Katarina NilsenPuco, Anne Hansen Ree, Tonje Bøyum Riste, Karin Semb, Eli Sihn Samdal Steinskog, Andreas Stensvold, Pål Suhrke, Øyvind Tennøe, Geir E. Tjønnfjord, Liv Jorunn Vassbotn, Eline Aas, Kristine Aasebø, Kjetil Tasken, Sigbjørn Smeland
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-11 (2022)
Abstract Background Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed attention has arisen d
Externí odkaz:
https://doaj.org/article/bc8aeb65ca3b4815a6a4cb94d009f0a6
Autor:
Carole Beck, Nicholas Paul Casey, Irene Persiconi, Neda Nejati Moharrami, Adam Sike, Yixin Jin, Jon Amund Kyte
Publikováno v:
Biomedicines, Vol 11, Iss 2, p 459 (2023)
Therapy employing T cells modified with chimeric antigen receptors (CARs) is effective in hematological malignancies but not yet in solid cancers. CAR T cell activity in solid tumors is limited by immunosuppressive factors, including transforming gro
Externí odkaz:
https://doaj.org/article/cc6b3e2ca1914ce4b4c0035c66af2581
Autor:
Åslaug Helland, Hege G. Russnes, Gro Live Fagereng, Khalid Al-Shibli, Yvonne Andersson, Thomas Berg, Line Bjørge, Egil Blix, Bodil Bjerkehagen, Sigmund Brabrand, Marte Grønlie Cameron, Astrid Dalhaug, Dalia Dietzel, Tom Dønnem, Espen Enerly, Åsmund Flobak, Sverre Fluge, Bjørnar Gilje, Bjørn Tore Gjertsen, Bjørn Henning Grønberg, Kari Grønås, Tormod Guren, Hanne Hamre, Åse Haug, Daniel Heinrich, Geir Olav Hjortland, Eivind Hovig, Randi Hovland, Ann-Charlotte Iversen, Emiel Janssen, Jon Amund Kyte, Hedda von der Lippe Gythfeldt, Ragnhild Lothe, Jo-Åsmund Lund, Leonardo Meza-Zepeda, Monica Cheng Munthe-Kaas, Olav Toai Duc Nguyen, Pitt Niehusmann, Hilde Nilsen, Katarina Puco, Anne Hansen Ree, Tonje Bøyum Riste, Karin Semb, Eli Sihn Samdal Steinskog, Andreas Stensvold, Pål Suhrke, Øyvind Tennøe, Geir E. Tjønnfjord, Liv Jorunn Vassbotn, Eline Aas, Kristine Aasebø, Kjetil Tasken, Sigbjørn Smeland
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-2 (2022)
Externí odkaz:
https://doaj.org/article/d1675781ce0d4327ba7f57f4b202f48a
Autor:
Hanne A. Eide, MD, Ingerid Skjei Knudtsen, MSc, Vandana Sandhu, PhD, Ayca M. Løndalen, MD, Ann Rita Halvorsen, MSc, Azadeh Abravan, MSc, Elin H. Kure, PhD, Trond V. Bogsrud, MD, PhD, Odd Terje Brustugun, MD, PhD, Jon Amund Kyte, MD, PhD, Eirik Malinen, PhD, Åslaug Helland, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 3, Iss 2, Pp 130-138 (2018)
Purpose: Radiation therapy effectively kills cancer cells and elicits local effects in the irradiated tissue. The aim of this study was to investigate the kinetics of cytokines in the serum of patients with lung cancer undergoing radiation therapy an
Externí odkaz:
https://doaj.org/article/2d9cf0ea7ca544a9a5e11ec83551453d
Publikováno v:
OncoImmunology, Vol 8, Iss 4 (2019)
Adoptive cell therapy (ACT) with retargeted T cells has produced remarkable clinical responses against cancer, but also serious toxicity. Telomerase is overexpressed in most cancers, but also expressed in some normal cells, raising safety concerns. W
Externí odkaz:
https://doaj.org/article/0f3fa1a201b24142b902978565ba5d00
Autor:
Shakila Jabeen, Jaime A. Espinoza, Lilly Anne Torland, Manuela Zucknick, Surendra Kumar, Vilde D. Haakensen, Torben Lüders, Olav Engebraaten, Anne-Lise Børresen-Dale, Jon Amund Kyte, Pavel Gromov, Bjørn Naume, Vessela Kristensen, Irina Gromova, Xavier Tekpli
Publikováno v:
OncoImmunology, Vol 8, Iss 2 (2019)
Cancers elicit an immune response by modifying the microenvironment. The immune system plays a pivotal role in cancer recognition and eradication. While the potential clinical value of infiltrating lymphocytes at the tumor site has been assessed in b
Externí odkaz:
https://doaj.org/article/916d29b9b703470980e669bea57b6e3e